Viridian Therapeutics Inc
Statements
Cash Flow
Viridian Therapeutics Inc (VRDN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -105 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.1 | -1.9 | -8.2 | -7.1 | -5.7 | -7.2 | -7.4 | -4.5 | -6.8 | -8.2 | -12 | -7.2 | -9.3 | -7.8 | -8.5 | -6.8 | -5.1 | -9.4 | -12 | -15 | -12 | -17 | -21 | -18 | -21 | -34 | -62 | -45 | -39 | -38 | -45 | -46 | -68 | -73 | -93 | -75 | -85 | -24 | -120 | -105 | -333 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | -13 | 0.1 | 0.1 | 0.1 | 0.1 | -0.9 | 0.1 | 0.1 | -0.5 | |
| 0.1 | 0.7 | 0.4 | 0.6 | 0.7 | 0.7 | 0.8 | 1.0 | 1.0 | 0.9 | 1.0 | 1.1 | 0.9 | 1.0 | 0.7 | 0.6 | 0.6 | 1.7 | 3.2 | 3.8 | 4.0 | 3.5 | 4.7 | 4.9 | 4.9 | 5.3 | 15 | 12 | 14 | 26 | 13 | 12 | 8.7 | 9.0 | 10 | 11 | 11 | 12 | 13 | 17 | 54 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1.1 | 0.7 | 0.5 | 0.9 | 74 | 3.3 | 3.0 | 4.0 | 11 | 4.7 | 4.8 | 5.5 | 5.3 | 15 | 17 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | 2.1 | -1.7 | -0.5 | -0.6 | -1.7 | -3.7 | 3.1 | 1.2 | 1.2 | -1.2 | 0.6 | 1.0 | 1.2 | -1.3 | -1.3 | -0.3 | 7.3 | 3.5 | 0.4 | -3.1 | 1.0 | -0.4 | 6.2 | 2.9 | 7.3 | -6.3 | -4.7 | -4.1 | 5.6 | -5.0 | 11 | -6.2 | 0.5 | -14 | 16 | -60 | 81 | -21 | 3.4 | 3.0 | |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.3 | 0.4 | 0.0 | 0.0 | 0.1 | 0.3 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.0 | 1.3 | 1.7 | |
| 3.0 | 1.0 | 1.2 | -0.1 | -0.1 | 0.0 | -0.1 | -33 | -6.0 | 9.1 | -2.8 | 13 | 11 | 7.0 | 2.0 | -0.1 | -0.1 | -52 | 11 | -11 | 6.3 | -80 | 8.9 | 14 | 43 | -181 | -13 | 41 | 48 | -170 | -143 | 62 | -85 | -63 | 100 | 76 | 126 | -339 | 77 | -231 | -367 | |
| 0.0 | -0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 87 | 1.3 | 7.1 | 117 | 0.2 | 0.1 | 0.0 | 291 | 0.2 | 0.3 | 3.1 | – | 0.3 | 0.4 | – | 0.3 | – | – | 0.6 | 1.1 | -1.1 | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -1.0 | -1.0 | 1.4 | -9.0 | -9.0 | – | – | 4.6 | 4.6 | 4.6 | 4.6 | 0.4 | 0.4 | – | – | – | – | – | – | – | 0.0 | – | – | – | – | – | – | – | |
| 0.0 | -0.1 | 39 | -0.8 | 2.2 | 12 | 38 | 2.7 | 1.1 | 0.0 | 0.2 | 0.0 | -0.9 | 0.8 | 18 | 1.3 | 4.6 | 78 | 1.3 | 7.1 | 117 | 0.2 | 0.7 | 4.6 | 291 | 26 | 8.2 | 3.1 | 15 | 199 | 177 | 0.1 | 245 | 36 | 9.2 | 0.8 | 11 | 406 | 6.4 | 325 | 748 | |
| -1.2 | -2.0 | 32 | -7.9 | -3.5 | 4.6 | 31 | -35 | -12 | 0.9 | -14 | 5.8 | 0.9 | 0.0 | 11 | -5.5 | -0.5 | 16 | 0.6 | -19 | 111 | -97 | -11 | 0.4 | 313 | -189 | -67 | -1.4 | 25 | -8.8 | -11 | 16 | 93 | -101 | 17 | 1.1 | 52 | 43 | -36 | -11 | 48 | |
| -1.1 | -1.9 | -8.2 | -7.2 | -5.7 | -7.3 | -7.5 | -4.6 | -7.0 | -8.2 | -12 | -7.2 | -9.3 | -7.8 | -8.5 | -6.8 | -5.1 | -9.4 | -12 | -15 | -12 | -17 | -21 | -18 | -21 | -34 | -62 | -46 | -39 | -38 | -45 | -46 | -68 | -73 | -93 | -75 | -85 | -24 | -120 | -107 | -335 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.